The guy on this report makes a good point. We have
Post# of 154481
(Total Views: 722)
Posted On: 11/10/2020 8:14:26 PM
The guy on this report makes a good point. We have a few emergency use authorizations but no approvals...NP is going for the big one, approval because that starts the domino affect for all other indications.
Personally I'm not angry about NP not going for M/M because in reality we only had like 46 patients that qualified for the subset where we showed promise. It was good promise, but not 400+ patients that Lilly had. So I could see the FDA wanting more than 40 patients from us to prove it.
One thing I find interesting that makes us unique is these big pharmas with all their money and scientists, can't seem to explain how their drug "works". They are concentrating on vaccines or attacking the virus which the FDA also seems to be stuck on. They also seem to be throwing darts at endpoints and changing to endpoints that fit whats happening with patients because they still don't fully understand what covid does to the body.
What we have is
1. a drug that works
2. we know why it works vs covid
3. we know how it works against covid
4. we understand the stage at which it starts working
So from what I can tell. Big pharma has the vaccine and early stage treatments, but if they don't work we have everything after that from moderate to severe to possibly long haulers...and a pristine safety record to boot.
So market knee jerk reactions are "fun" to watch, but many of these retail investors rely on the major media to feed them whats happening without deep due diligence.
I'm not worried at all the subtle signs are there that CYDY is on the upswing
1. This new york spot mentioned CYDY in the same breath as LLY and REGN
2. Multiple published papers now out on leronlimab and how it works
3. multiple big city news outlets referencing our trial
4. OWS, a government entity, knows who we are and actually talked to us
Personally I'm not angry about NP not going for M/M because in reality we only had like 46 patients that qualified for the subset where we showed promise. It was good promise, but not 400+ patients that Lilly had. So I could see the FDA wanting more than 40 patients from us to prove it.
One thing I find interesting that makes us unique is these big pharmas with all their money and scientists, can't seem to explain how their drug "works". They are concentrating on vaccines or attacking the virus which the FDA also seems to be stuck on. They also seem to be throwing darts at endpoints and changing to endpoints that fit whats happening with patients because they still don't fully understand what covid does to the body.
What we have is
1. a drug that works
2. we know why it works vs covid
3. we know how it works against covid
4. we understand the stage at which it starts working
So from what I can tell. Big pharma has the vaccine and early stage treatments, but if they don't work we have everything after that from moderate to severe to possibly long haulers...and a pristine safety record to boot.
So market knee jerk reactions are "fun" to watch, but many of these retail investors rely on the major media to feed them whats happening without deep due diligence.
I'm not worried at all the subtle signs are there that CYDY is on the upswing
1. This new york spot mentioned CYDY in the same breath as LLY and REGN
2. Multiple published papers now out on leronlimab and how it works
3. multiple big city news outlets referencing our trial
4. OWS, a government entity, knows who we are and actually talked to us
(13)
(0)